Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of HIV-1 and Aging on Mucosal Vaccine Responses
NCT03729778Phase 1Active, not recruiting
- Sponsor
- VA Eastern Colorado Health Care System
- Start
- Jan 2017
- Primary completion
- Mar 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of Prevnar 13 in pneumococcal infection (2 arms), sponsored by VA Eastern Colorado Health Care System. Primary endpoints: Pneumococcal specific IgG levels in BronchoAlveolar Lavage fluid and Nasopharyngeal Fluid at 1 month and Pneumococcal specific IgG levels in serum at 1 month. Started Jan 2017; status: active, not recruiting.
02
Drugs
Prevnar 13
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT03729778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03729778.